Internal Medicine

Investigators believe the novel monoclonal antibody may be a suitable agent in patients with major bleeding risk or those undergoing surgery.

New late-breaking ACC 2022 data support the use of antihypertensive therapy to reduce risk of events including preeclampsia and neonatal death among at-risk expecting mothers.

An analysis of Medical Expenditure Panel Survey data suggests minority patients were less likely to undergo recommended exams and more likely to develop diabetic eye complications than their White counterparts.

Late use of steroids among patients with AIN shows now indication of further recovery and poses an additional risk of exposing patients to adverse effects.

The costs related to Medicare for OACC increased by about 4% between 2012-2017 for patients with end-stage kidney disease for kidney transplantation.

The agency cited an increased risk of thromboembolic events driven by vascular access thrombosis in dialysis patients and increased risk of drug-induced liver injuries.

On March 29, Antares Pharma announced the FDA granted approval to their oral testosterone replacement therapy option, testosterone udecanoate (TLANDO), for conditions associated with a deficiency or absence of endogenous testosterone or hypogonadism in adult males.

With the newest indication, the GLP-1 agonist is now available in 3 different doses for diabetic adults.

Data from Australia show a T-cell antigen-inducing vaccine was unable to provide greater prevention of flu incidence than a placebo.

An analysis of data from 2013-2015 provides insight into the impact of Medicaid expansion under the Affordable Care Act on rate of major diabetes-related amputations and suggests a shift in the distribution of uninsured patients may have driven reductions observed in the study.

Cross-sectional analysis of national survey data suggest students with multiple marginalized identities are more prone to treatment that could lead to burnout.

Patients with Fabry disease who received treatment with PRX-102 every 4 weeks displayed a stable condition at the end of the trial.

Dr. Bajona highlights the patient risks of HCM, new advances in treatment options, and the importance of screening efforts.

In 2020 many clinics shifted to telehealth or reduced-contact practices which applied to medication abortions. Physicians relied solely on history-based screening instead of ultrasonography or pelvic exams during this time and investigators analyzed the data.

A user fee goal date of August 17, 2022 has been assigned to teplizumab.

Overall tobacco use declined among adults since 2019—but many from varying sociodemographic backgrounds are still reporting high use.

New data support the continued assessment of the investigative drug for adults with SLE.

After more promising long-term data, Apellis announced plans to seek regulatory approval. An investigator explains what value it could bring to patients.

Phase 3 data show the C3 inhibitors' sustained benefit for the common form of vision loss. A primary author explains the significance of the new findings.

After a review of the available evidence, the USPSTF concluded there was insufficient evidence to provide recommendations on screening for eating disorders among adults and adolescents.

New data show the highest quintile of census-reported parental income is far more represented among future physicians than lower income levels, regardless of race.

ChristianaCare’s Gene Editing Institute experts join the podcast to discuss the latest developments in gene editing.

USPSTF experts noted a need for research into the benefits and harms of screening adults and adolescents without signs or symptoms.

As influenza A(H3N2) remains the most prevalent subtype in the US, investigators estimated the available flu shot is not significantly preventing positive cases.

Using multiple composite scores to assess dietary quality, investigators use data from 9 NHANES cycles to provide an overview of the declining diet quality among older adults in the US from 2001-2018.

Primary results from these 2 phase 3 trials demonstrated efficacy and safety of the biologic through 16 weeks in patients with atopic dermatitis, but longer-term outcomes remained unknown.

The clinical trial of efanesoctocog alfa provided positive top-line results for treating patients with severe Hemophilia

Research from Wake Forest shows patients are more comfortable sharing concerning matters when screened on a tablet app compared with speaking to a nurse.

An increase in annual prevalence of beneficiaries with diabetes was observed in those who had ≥1 claim for DME (1.0% to 3.3%) and DME/VTDR (2.8% to 4.3%).